Home » USA Broker Ratings » Illumina – Consenus Indicates Potential 17.5% Upside

Illumina – Consenus Indicates Potential 17.5% Upside

Illumina with ticker code (ILMN) have now 16 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 371 and 220 with a mean TP of 322.5. Now with the previous closing price of 274.42 this would indicate that there is a potential upside of 17.5%. The day 50 moving average is 265.76 and the 200 day MA is 300.25. The company has a market cap of $39,550m. Find out more information at: http://www.illumina.com

Illumina provides sequencing and array-based solutions for genetic and genomic analysis. The company offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array. It also provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and noninvasive prenatal testing, as well as products support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals; and pharmaceutical, biotechnology, and commercial molecular diagnostic laboratories, as well as consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina has a collaboration with Roche to broaden the adoption of distributable next-generation sequencing-based (NGS) testing in oncology. The company operates in North America, Europe, Latin America, the Asia-Pacific region, the Middle East, China, and Africa. Illumina was founded in 1998 and is headquartered in San Diego, California.

Join us on our new LinkedIn page

Follow us on LinkedIn